Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310733 | 0.88 | IGF1R (0.34) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309929 | 0.88 | MAP4K1 (0.33) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309386 | 0.88 | JAK2 (0.37) | MAP4K1IGF1RCYP1A2CYP2C19 | |
| SCHEMBL24309769 | 0.87 | MAP4K1 (0.32) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309840 | 0.86 | MAP4K1 (0.32) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24310201 | 0.86 | MAP4K1 (0.32) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24310088 | 0.86 | IGF1R (0.31) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309897 | 0.86 | DHODH (0.32) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24310417 | 0.84 | LMNA (0.33) | IGF1RCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL29566849 | 0.84 | SCN9A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |